Chronic heart failure in adults: diagnosis and management

consider liaising with a renal physician. [2018, amended 2025] 1.7 Starting and monitoring medication use Tailoring treatment 1.7.1 Use the person's medical history and findings from their clinical assessment, their frailty status, prognosis and preferences when deciding: • which specific medicines and medicine combinations to use (see recommendations 1.4.1, 1.4.3, 1.4.4 and 1.5.1 to 1.5.5) • the order and timing for introducing each medicine • the initial dose of each medicine and any subsequent dose increments • when and how to optimise the dose of each medicine. See also NICE's guideline on shared decision making. [2025] 1.7.2 Primary care prescribers should consider seeking advice from a heart failure specialist before starting someone on an angiotensin receptor-neprilysin inhibitor (ARNI). [2025] For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on starting and monitoring medicine use. Full details of the evidence and the committee's discussion are in evidence review A: medicines for heart failure with reduced ejection fraction. ACE inhibitors, ARNIs, ARBs and MRAs 1.7.3 Before prescribing an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor-neprilysin inhibitor (ARNI), angiotensin II receptor blocker (ARB) or mineralocorticoid receptor antagonist (MRA), measure the
